Alvotech and Sandoz Expand Partnership Covering Biosimilar Portfolio Across Multiple Markets

fork_in_the_road · 2026-02-17T22:01:34+00:00

Alvotech has partnered with Sandoz for the supply and commercialization of biosimilars across key regions. While Sandoz handles regulatory and market aspects, Alvotech focuses on product development and manufacturing, aiming to enhance market access and address therapeutic needs.

fork_in_the_road

2026-02-17 22:01:34

Abstract generation in progress

Alvotech (ALVO) has announced a significant strategic partnership with Sandoz (SDZ.SW), establishing supply and commercialization agreements that cover multiple biosimilar product candidates across key regions. Under this arrangement, Sandoz will assume responsibility for regulatory submissions, market distribution, and commercialization efforts in the designated territories, while Alvotech maintains control over product development, global clinical operations, and manufacturing capabilities.

Covering Therapeutic Innovation Across North America and Asia-Pacific

The partnership spans three distinct geographic markets with tailored product portfolios. In the Canadian market, the agreement encompasses a single biosimilar candidate in ophthalmology, specifically formulated as a prefilled syringe designed for intravitreal injection—a specialized delivery method for eye treatments. Meanwhile, the partnership covering Australia and New Zealand extends to three biosimilar candidates spanning immunology and gastroenterology therapeutic areas, reflecting the diverse clinical needs of these markets.

Division of Responsibilities in the Collaborative Framework

The structural agreement clearly delineates operational roles: Alvotech retains full oversight of drug development, clinical trial execution across global operations, and manufacturing operations, assuming the supplier position by providing finished products to Sandoz. Sandoz, as the commercialization partner, leverages its established regulatory expertise and market distribution infrastructure in each jurisdiction to drive market penetration and patient access.

Market Response and Financial Outlook

At the time of announcement, Sandoz shares were trading at 60.72 Swiss francs, reflecting a 0.75% decline in trading activity. This partnership demonstrates confidence in the biosimilar market’s growth potential and represents a strategic approach to sharing development risks while maximizing market reach across priority therapeutic segments.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.